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A major problem in detecting diet-disease associations in nutritional cohort studies is measurement error in self-
reported intakes, which causes loss of statistical power. The authors propose using biomarkers correlated with
dietary intake to strengthen analyses of diet-disease hypotheses and to increase statistical power. They consider
combining self-reported intakes and biomarker levels using principal components or a sum of ranks and relating the
combined measure to disease in conventional regression analyses. They illustrate their method in a study of the
inverse association of dietary lutein plus zeaxanthin with nuclear cataracts, using serum lutein plus zeaxanthin as
the biomarker, with data from the Carotenoids in Age-Related Eye Disease Study (United States, 2001–2004). This
example demonstrates that the combined measure provides higher statistical signiﬁcance than the dietary mea-
sure or the serum measure alone, and it potentially provides sample savings of 8%–53% over analysis with dietary
intake alone and of 6%–48% over analysis with serum level alone, depending on the deﬁnition of the outcome
variable and the choice of confounders entered into the regression model. The authors conclude that combining
appropriate biomarkers with dietary data in a cohort can strengthen the investigation of diet-disease associations
by increasing the statistical power to detect them.
carotenoids; cataract; lutein; ranks; sample size
Abbreviations: CAREDS, Carotenoids in Age-Related Eye Disease Study; WHI, Women’s Health Initiative.
Measurementerrorindietaryreportingpresentsamajor
challenge to nutritional epidemiology (1). In univariate
models, these errors cause underestimation of relative
risks and greatly impair the statistical power to detect
a diet-disease association. In multivariate models, they
cause biases of unpredictable magnitude and direction
in the estimation of relative risks (2). Most of the statis-
tical work concerning the effect of dietary measurement
error on results in nutritional epidemiology focuses on the
validation of questionnaires or the deattenuation of esti-
mated relative risks and odds ratios (3, chapters 6 and 12).
However, methods of deattenuation do not increase the
statistical power with which diet-disease associations
may be detected. On the contrary, the methods usually
further decrease, by a small amount, the statistical power
(4, p. 60).
We previously described a method for increasing the
statistical power of studies of diet-disease associations by
combining dietary biomarker levels with usual self-reported
dietary intakes (5). We showed, through computer simula-
tions, that such a method potentially leads to an increase in
power and a decrease in required sample size in epidemio-
logic studies (5). In this paper, we illustrate the method
using data from the Carotenoids in Age-Related Eye Dis-
ease Study (CAREDS) (6) on the inverse association be-
tween dietary lutein plus zeaxanthin and nuclear cataracts,
and we show that it provides some modest gains in statistical
power.
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Study population
CAREDS is an ancillary study of the Women’s Health
Initiative (WHI) Observational Study, a prospective cohort
study of 93,676postmenopausal women aged 50–79 yearsat
enrollment recruited from 40 sites around the United States
(7, 8). The CAREDS population included women enrolled
at 3 of the sites: University of Wisconsin (Madison), Uni-
versity of Iowa (Iowa City), and Kaiser Center for Health
Research (Portland, Oregon). Women with reliable food fre-
quency questionnaire data who reported total energy  600
kcal (2,510 kJ) and  5,000 kcal (20,920 kJ) and who re-
ported intakes of lutein plus zeaxanthin above the 78th and
below the 28th percentiles, as assessed at the WHI baseline
examination in 1994–1998, were considered for recruitment
in CAREDS. Of the 3,143 eligible women, 96 had died or
were lost to follow-up between WHI recruitment and the
time of enrollment in CAREDS in 2001–2004. Of those
remaining, 2,005 agreed to participate (66%). Of these
women, 194 were excluded; one participant provided unreli-
able dietary information, 32 reported a history of trauma to
both eyes, one reported cataract extraction before the age of
40 years, 132 had missing or ungradable nuclear lens pho-
tographs, and 28 had missing covariate data. The ﬁnal ana-
lytical set included 1,811 women. Further details on the
study design have already been reported (6). All procedures
conformed to the Declaration of Helsinki and were approved
by the institutional review board at each university.
Dietary assessment
Dietary intake was assessed at WHI Observational Study
baseline (1994–1998) by using the WHI semiquantitative
food frequency questionnaire, which was previously pre-
tested (9). Nutrient and food group estimates were com-
puted at the Fred Hutchinson Cancer Research Center,
Seattle, Washington.
Serum lutein and zeaxanthin
Serum samples were collected after 10 or more hours of
fasting at the WHI baseline examinations (1994–1998) and
were analyzed for lutein and zeaxanthin (sum of their trans
isomers) (6). Serum lutein and zeaxanthin measurements
were available from 1,787 women.
Age-related nuclear cataract
Participants underwent lens photography and eye exami-
nations during the study visits at CAREDS baseline between
2001 and 2004 (6). They also completed a questionnaire que-
rying about time of cataract surgery in each eye; trauma to
eyes; physician-diagnosed history of cataract, glaucoma, and
macular degeneration; and treatments or lifestyle changes
that accompanied these conditions. Information on family
history of nuclear cataract was also collected.
Our primary outcome was nuclear cataract, deﬁned as
a nuclear sclerosis severity score of 4 or greater in the worst
eye and/or a history of cataract extraction in either eye; all
women in the data set had information that used this deﬁni-
tion (N ¼ 1,811). Women who had a history of cataract
extraction, but who lacked evidence of a nuclear sclerosis
severity score of 4 or greater, were still included as cases
because it has been shown that the most likely indication for
cataract surgery is photographically evident cataracts in the
nuclearregionofthelens(10).Wealsoanalyzedasecondary
outcome, nuclear sclerosis only with a severity score of 4 or
greater, which could be assessed in the 1,580 women who
had at least one natural lens for which lens photographs
were gradable.
Covariates
The questionnaire completed at CAREDS baseline col-
lected information on age, family history of cataract, ultra-
violet B sunlight exposure, and use of dietary supplements.
Other lifestyle and medical history data were available from
the WHI baseline questionnaire (e.g., height, weight, edu-
cation, smoking, physical activity, use of hormone replace-
ment therapy, multivitamin use, pulse pressure, alcohol
consumption, diabetes, cardiovascular disease, and hyper-
tension). Iris color was determined from photographs taken
at the CAREDS eye examination.
Statistical methods
We investigated 3 ways of analyzing reported dietary
lutein plus zeaxanthin intake and lutein plus zeaxanthin
serum level; the third one combines the self-report and bio-
marker. Each analysis involved a logistic regression model
with a set of confounding variables as well as one of the
following exposure measures:
1. Reported dietary intake: food frequency questionnaire–
reported lutein plus zeaxanthin.
2. Biomarker level: serum lutein plus zeaxanthin.
3. Howe’s score with ranks: participants are ranked from
lowest to highest value for reported dietary intake and
biomarker level. The 2 ranks are then summed. This is
a special case of Howe’s method (11) in which subjects
are placed in one of k quantiles (1, 2, ..., k) of dietary
intake and in one of k quantiles (1, 2, ..., k) of biomarker
level, and the subject is given a score equal to the sum of
the 2 quantiles. In the version we used, the number of
quantiles k is set equal to the sample size; it is expected
to be the most efﬁcient version of Howe’s method.
In all analyses, we used the logarithm of the reported
intake of lutein plus zeaxanthin, and serum lutein plus zeax-
anthin raised to the power 0.2, to achieve approximately
normally distributed variables. These transformations were
chosen by observing the shape of the histograms after var-
ious power transformations.
We ran models for both the primary nuclear cataract
outcome and for the secondary nuclear sclerosis severity
outcome. We investigated 2 sets of confounders. First, we
included only age, the strongest confounder; second, we
added confounders used in the CAREDS analyses (6):
smoking (current/past/never), iris color (blue/green/light
brown/dark brown or black), body mass index (kg/m
2),
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activity (total metabolic equivalents/week), hormone re-
placement therapy (current/past/never), and pulse pressure
(mm Hg).
To compare the distribution of each variable between
cases (nuclear cataract) and controls (no nuclear cataract),
we used t tests, Wilcoxon tests, or chi-squared tests accord-
ing to the type of variable. We estimated the logarithm of
odds ratios from logistic regression models, and we calcu-
lated the associated Wald z statistic. We computed the odds
ratio for the 90th percentile versus the 10th percentile of
the distribution of each exposure variable to compare the
strength of association with disease across the different
measures of exposure. We computed sample size savings
resulting from use of one exposure measure compared with
another as the ratio of the square of the Wald z statistics for
their respective coefﬁcients. For example, suppose that the
z statistic for self-reported diet was 2.25 and for the com-
bined measure of diet and biomarker was 3.29. Then, the
sample size required for the combined measure is estimated
to be (2.25/3.29)
2 ¼ 0.47 times the sample size required for
the self-reported diet. Similarly, relative reductions in the
detectable effect size were calculated as the ratio of the
Wald z statistics for the 2 models.
RESULTS
A total of 738 participants had a nuclear cataract. Table 1
presents the characteristics of these participants and 1,073
controls without nuclear cataract, as deﬁned by the primary
outcome measure. Patients with nuclear cataract had a much
higher mean age than controls (73 years vs. 67 years). The
groups differed with respect to several other variables in-
cluding serum lutein plus zeaxanthin levels, physical activ-
ity, hormone replacement therapy use, pulse pressure, and
multivitamin use (Table 1).
Table 1. Selected Characteristics of the Participants in the CAREDS Study, United States,
2001–2004, by Primary Nuclear Cataract Outcome
a
Variable
Controls (N 5 1,073) Cases (N 5 738)
P Value
b
Mean (SD) % Mean (SD) %
Serum lutein þ zeaxanthin,
lmol/L
c 0.33 (0.16) 0.30 (0.14) 0.003
Dietary lutein þ zeaxanthin,
lg/day
1,848 (1,284) 1,788 (1,226) 0.5
Age, years 67 (6) 73 (6) <0.001
Body mass index, kg/m
2 27.3 (5.8) 27.8 (5.9) 0.07
Smoking status 0.6
Never 58 57
Former 38 40
Current 4 4
Physical activity, total
METs/week
15.4 (15.1) 14.1 (14.5) 0.04
Hormone replacement
therapy use
<0.001
Never 30 39
Former 12 15
Current 58 46
Iris pigmentation 0.14
Blue 42 41
Green 27 25
Light brown 25 25
Dark brown/black 6 10
Pulse pressure, mm Hg 50 (13) 57 (15) <0.001
Energy intake, kcal/day
d 1,646 (650) 1,603 (595) 0.15
Multivitamin without
minerals use
4 2 0.01
Abbreviations: CAREDS, Carotenoids in Age-Related Eye Disease Study; MET, metabolic
equivalent; SD, standard deviation.
a Nuclear sclerosis severity score of  4 and/or a history of cataract extraction in either eye.
b Two-sided P value for test of difference between cases and controls (t, Wilcoxon, or chi-
square test as appropriate to each variable).
c Data available for 1,060 controls and 727 cases.
d 1 kcal ¼ 4.184 kJ.
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in Table 2. For each outcome deﬁnition and each set of
covariates, we compared the results of using as the exposure
measure 1) food frequency questionnaire–reported intake of
lutein plus zeaxanthin, 2) serum lutein plus zeaxanthin, and
3) Howe’s score with ranks.
For the primary nuclear cataract outcome, with both
sets of covariates, the odds ratio for the serum level was
stronger than for reported dietar yi n t a k e .I nb o t hc a s e s ,t h e
odds ratio for the combination of serum and reported in-
take was slightly stronger than that for serum alone, and
the z values were correspondingly larger. When we com-
pared the analysis using reported intake with the analysis
using serum level, adjusted for age or in the full model, we
estimated that serum level could achieve the same statis-
tical power with only 50% or 59%, respectively, of the
sample size. Use of the combined exposure measure re-
duced this sample size further to 47% or 52%, respec-
tively. When we compared the analysis using serum
level with the one using the combined measure, we esti-
mated that the latter could achieve the same statistical
power with 94% (47%/50%) or 88% (52%/59%), respec-
tively, of the sample size.
For the secondary nuclear sclerosis severity outcome,
with both sets of covariates, the odds ratios for the serum
level and the reported dietary intake were quite similar; in
one case, the serum-level odds ratio was slightly stronger
(0.72 vs. 0.74) and in one case it was weaker (0.78 vs. 0.74).
Correspondingly, whereas in the age-adjusted model the
serum level provided an estimated 15% sample savings over
the dietary report, in the full model, the serum measure re-
quired an estimated 76% larger sample to achieve the sta-
tistical power of the analysis with reported intake. In both
cases, the odds ratio for the combination of serum and re-
ported intake was slightly stronger than the stronger of the 2
separate exposures, and the z values were also correspond-
ingly larger. In the analysis with the full set of covariates,
conventional statistical signiﬁcance was achieved by using
the combined measure (z ¼ 1.99) but not the separate mea-
sures (z ¼ 1.91 and z ¼ 1.44, respectively). When we com-
pared the analysis with reported intake with that using the
combined measure, we estimated that the latter could
achieve the same statistical power with only 63% or 92%
of the sample size, respectively. Compared with serum level,
the combined measure could achieve the same statistical
power with 74% (63%/85%) or 52% (92%/176%) of the
sample size, respectively. Table 2 also shows the corre-
sponding reductions in detectable effect sizes under equal
sample size.
DISCUSSION
In the example presented, we have demonstrated an as-
sociation of nuclear cataract risk with both reported dietary
Table 2. Odds Ratios and Sample Size Savings Estimated From Logistic Regression Relating Nuclear Cataract
Outcomes to Dietary and Serum Lutein and Zeaxanthin in the CAREDS Study, United States, 2001–2004
Outcome (No. of Cases/
No. of Noncases) Covariates
Lutein/
Zeaxanthin
Measure
OR
a 95% CI Wald z
Value
b
Sample
Size
Ratio
c
Detectable
Effect Size
Reduction, %
d
Primary
e (727/1,060) Age Diet 0.73 0.56, 0.96 2.25
f 1.0
Serum 0.64 0.49, 0.84 3.16
f 0.50 29
Diet þ serum
g 0.61 0.45, 0.82 3.29
f 0.47 32
Primary
e (724/1,059) Full
h Diet 0.77 0.57, 1.02 1.84 1.0
Serum 0.69 0.51, 0.94 2.38
f 0.59 23
Diet þ serum
g 0.66 0.48, 0.91 2.56
f 0.52 28
Secondary
i (450/1,111) Age Diet 0.74 0.54, 1.00 1.95 1.0
Serum 0.72 0.53, 0.98 2.10
f 0.85 7
Diet þ serum
g 0.66 0.47, 0.92 2.45
f 0.63 20
Secondary
i (447/1,110) Full
h Diet 0.74 0.54, 1.01 1.91 1.0
Serum 0.78 0.57, 1.09 1.44 1.76  33
Diet þ serum
g 0.70 0.50, 0.99 1.99
f 0.92 4
Abbreviations: CAREDS, Carotenoids in Age-Related Eye Disease Study; CI, conﬁdence interval; OR, odds ratio.
a Odds ratio between the 90th and 10th percentile of the exposure distribution.
b Wald z value of the regression coefﬁcient for the continuous variable.
c The ratio of sample sizes required to produce the same statistical power as that based on the diet-only analysis.
d The reduction in effect size that can be detected with the same statistical power as in the diet-only analysis given
the same sample size.
e Examination þ history.
f P < 0.05 using a 2-sided Wald test.
g Howe’s method based on ranks.
h Including the covariates age (continuous), smoking (never, past, current), iris color (blue, green, light brown, dark
brown/black), bodymassindex (continuous), multivitamin use(yes, no),physicalactivity (continuous), pulsepressure
(continuous), and hormone replacement therapy use (yes, no).
i Examination only.
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ation with reported dietary lutein/zeaxanthin is somewhat
weaker than that reported in the original publication, with
odds ratios between the 90th and 10th percentiles of approx-
imately 0.75 compared with approximately 0.65 reported
originally (6). The difference is due to our having modeled
the risk according to a continuous intake model rather than
in quintiles. Nevertheless, both our analysis and that pre-
sented previously (6) clearly demonstrate the association.
We have shown in our analysis that combining a bio-
marker of dietary intake with self-reported dietary intake
can increase the statistical power for detecting a diet-disease
association. The gains demonstrated in this example are
rather similar to those reported previously in computer sim-
ulations (5). Besides using Howe’s method for combining
measures, we also applied a principal components method,
described in detail previously (5). Given that the principal
components results were very similar to those using Howe’s
method, we have reported only the latter here.
The gains obtained from combining a marker with a self-
report may be considered in one of two ways. Firstly, we
may ask what we gain from introducing a marker into
a study. To answer this question, the correct comparison is
between the combination of marker and self-report versus
self-report alone, or between the marker alone and self-
report alone. Here, we have demonstrated substantial efﬁ-
ciencies, equivalent to halving the sample size, although
the monetary cost of introducing the marker may be high.
Secondly, we may ask what we gain from combining
a marker and a self-report when both are already included
in the study. In this case, the correct comparison is between
the combination and the best of either self-report or marker
alone. Here, the power gains we have demonstrated are
more modest, sometimes a few percent, sometimes a
20%–30% reduction in sample size. However, the monetary
cost of performing the combined analysis is essentially nil
because both measurements are already available.
There are several limitations to our suggested approach.
First, the measure of lutein in either the diet or serum might,
to some extent, reﬂect other aspects of diet that, in addition
to the effects of lutein itself, might also lower the risk of
nuclear cataract. These, rather than improved estimation of
lutein status, may explain stronger associations with cata-
ract. For example, women who have high, compared with
low, estimates of dietary lutein are likely to also have lower
intakes of fat and higher intakes (and blood levels) of many
other micronutrients that may lower risk of cataract (6).
Thus, the stronger associations with cataract may reﬂect
broader aspects of diet that are captured by a measure of
lutein in the serum rather than less error in measuring lutein
status. On the other hand, the gains in power demonstrated
here are rather close to those predicted from computer sim-
ulations of a simple model in which all gains were due to
reductions in measurement error (5).
Second, Howe’s score has no recognized units, being the
sum of 2 ranks. Nevertheless, as shown in Table 2, odds
ratios for the 90th versus the 10th percentile may be esti-
mated as a useful quantity to express the strength of the
association with disease. This measure is really no different
from the conventional odds ratio between highest and lowest
quintiles often used in epidemiologic research reports. The
combined approach proposed here could be used as an efﬁ-
cient means of establishing the existence of a nutrition-
disease association. Subsequent analyses could explore the
associations between dietary intake, biomarker level, and
disease risk in more depth, including, for example, whether
the dietary effect is mediated by the biomarker.
Use of the combined exposure measure will not always
increase statistical power over that obtained by using one
of the separate exposures. For example, if the reported in-
take were to demonstrate no association (estimated odds
ratio ¼ 1) with disease while the serum level were found
to be associated strongly (estimated odds ratio much greater
than 1), then the combined exposure measure would likely
have an estimated odds ratio intermediate between those for
the separate exposure measures and would have less power
than that for the serum-level analysis. The most successful
results from the combined exposure measurewill arisewhen
the associations for each separate exposure are of similar
strength, as occurs in the example presented here.
The markers that should be considered for combination
with dietary reports are those that have been shown in con-
trolled feeding studies to be modiﬁed by changes in the
relevant dietary intake. Then, if changes in the marker caus-
ally affect disease risk, it implies that dietary intakewill also
affect disease risk, thus justifying the combination of the 2
measures. Clearly, situations will arise in which no suitable
marker exists for the nutrient or food under study.
It is not essential that there be a high correlation between
biomarker and reported dietary intake. More important is
the biomarker’s correlation with true intake. To be helpful
in combination, this correlation should be similar to, or
higher than, the correlation between reported intake and true
intake (5). Information about these correlations may be
available from controlled feeding studies.
It would also be helpful if the biomarker were known not
to be affected by other risk factors for the disease. If other
risk factors were to affect the biomarker, then the associa-
tion between biomarker and disease would be at least partly
a result of confounding. In the worst case, modifying the
biomarker level through diet change might not affect dis-
ease. This problem of confounding has been an important
consideration in previous studies of biomarkers and disease.
If a strong risk factor for the disease is known to affect the
marker, that risk factor must be included in the disease risk
model to avoid ascribing its effect to nutritional causes. In
our study, smoking was included in the full model since it is
associated with nuclear cataract and may also lead to de-
pletion of lutein and zeaxanthin in blood, being a source of
free radicals and oxidative stress (12).
Including biomarker measurements for all participants in
a large study is a considerable challenge and can be ex-
tremely expensive. However, collecting biologic samples
from participants is no longer uncommon, and their uses
are manifold. Thus, the proposed approach will be feasible
for studies with an already established ‘‘biobank.’’ Note
that, for large prospective studies, the analytic cost of the
bioassays need not be prohibitive if analyses are based on
a nested case-control design. In view of the potential reduc-
tions of approximately 50% in sample size, it seems worth
840 Freedman et al.
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gets required for a study with and without biomarkers rele-
vant to the exposures of greatest interest.
The extent to which a dietary intake effect is mediated
by the biomarker is often unknown. Methods that perform
well under different disease risk models are therefore to be
encouraged. We found in previous simulation work (5) that
Howe’s methodseemedtodothis. Inthe scenarios examined,
it was uniformly superior to univariate dietary intake analy-
sis. It was also superior to univariate biomarker analysis un-
dertheno-mediationmodelandwasnotsubstantiallyinferior
tothatanalysisunderfullmediation.Thus,whentheextentto
which the biomarker mediates the dietary effect is unknown,
a combination approach would appear to be a good strategy.
In summary, we have provided an example of how com-
bining a biomarker of dietary intake with self-reported
dietary intake somewhat increases the statistical power to
detect a diet-disease association. The gains in statistical
power are fairly modest if compared with the best of the 2
separate exposure measures but are potentially useful in
a research area in which measurement error severely limits
our ability to elucidate such associations.
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